Albert Lobuglio is an Oncology physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 6 publications with 1,745 citations (h-index 6); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1802 6th Ave S
Np 2556
Birmingham, AL 352331932
Telephone
205-934-5077Registry record last updated 8 May 2012.
Clinical trials
- Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas
Sponsor: University of Alabama at Birmingham
- Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer
Sponsor: University of Alabama at Birmingham
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
NIH funding
15 NIH research awards on record, funded 1985–2003 per NIH RePORTER. The latest:
- COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
University of Alabama at Birmingham
FY2003$5,124,250P30CA013148 - COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
University of Alabama at Birmingham
FY2002$4,789,670P30CA013148 - NOVEL RADIOIMMUNOTHERAPY FOR OVARIAN CANCER
University of Alabama at Birmingham
FY2002$336,365R01CA084152
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Suppression of Human Anti-Mouse Antibody Response to Murine Monoclonal Antibody L6 by Deoxyspergualin: A Phase I Study
Advances in experimental medicine and biology
1994 - Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against Endotoxin
New England Journal of Medicine
1991
Similar KOLs
Other experts from the same institution or the same specialty.
Vera Bittner
University of Alabama at Birmingham
Richard Whitley, MD
University of Alabama at Birmingham
David Standaert, MD, PhD
University of Alabama at Birmingham
Erik Roberson
University of Alabama at Birmingham
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”